Status:
COMPLETED
The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension
Lead Sponsor:
Regional Hospital Holstebro
Conditions:
Essential Hypertension
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in patients with essential hypertension - during baselin...
Eligibility Criteria
Inclusion
- Age 18 - 65 years.
- Body mass index less or equal to 30 kg/m2.
- Women must use oral hormonal anticonceptive drugs, use intrauterine anticonceptive device, be sterilized / hysterectomized or be postmenopausal.
- Arterial hypertension, defined by 24 hour ambulatory blood pressure above 125 mmHg systolic or above 80 mmHg diastolic.
Exclusion
- History of myocardial infarction.
- History of stroke.
- Heart failure.
- Endocrine organ disease.
- Lung disease.
- Clinically significant abnormal biochemical screening of the blood regarding: B-hemoglobin, P-sodium, P-potassium, P-creatinine (under 200 µmol/L will be accepted), P-albumin, p-bilirubin, p-alaninaminotransferase, P-alkaline phosphatase, p-cholesterol and B-glucose.
- Clinically significant abnormal screening of the urine regarding: albumin and glucose (protein excretion below 0.5 g/L will be accepted).
- Renovascular hypertension.
- Malignant disease.
- Alcohol abuse.
- Usage of medical drugs besides antihypertensives or statins.
- Drug abuse.
- Pregnancy or breast feeding.
- Known intolerance or allergic to eprosartan or sodium nitroprusside.
- Blood donation within 1 month of the start of the study.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2008
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00438945
Start Date
January 1 2007
End Date
January 1 2008
Last Update
May 9 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medical Research, Holstebro Hospital
Holstebro, Denmark, 7500